Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Park, So Youn ^a   Park, Hyun J ^a   Moon, Song M ^a   Park, Ki Ho ^a   Chong, Yong P ^a   Kim, Mi Na ^a   Kim, Sung Han ^a   Lee, Sang Oh ^a   Kim, Yang S ^a   Woo, Jun H ^a   Choi, Sang Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Combination treatment; Pneumonia; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON;

ADULT; AGED; ARTICLE; BACTEREMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PATIENT CODING; PSEUDOMONAS PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; UNIVERSITY HOSPITAL;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84869069739     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-308     Document Type: Article

References (20)

1. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, Lee NY, Chung DR, Peck KR, Song JH. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection 2011, 39(4):309-318. 10.1007/s15010-011-0124-6, 21594653.
2. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011, 139(4):909-919. 10.1378/chest.10-0166, 21467058.
3. National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32(8):470-485. 10.1016/j.ajic.2004.10.001, 15573054, National Nosocomial Infections Surveillance System.
4. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011, 139(5):1172-1185. 10.1378/chest.10-0167, 21540216.
5. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009, 64(2):229-238. 10.1093/jac/dkp201, 19520717.
6. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978, 24(1):45-54. 10.1159/000237759, 412648.
7. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004, 328(7441):668-681. 10.1136/bmj.38028.520995.63, 381218, 14996699.
8. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4(8):519-527. 10.1016/S1473-3099(04)01108-9, 15288826.
9. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011, 31(6):598-608. 10.1592/phco.31.6.598, 21923444.
10. Heyland DK, Dodek P, Muscedere J, Day A, Cook D, . Canadian Critical Care Trials Group Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36(3):737-744. 10.1097/01.CCM.0B013E31816203D6, 18091545, Canadian Critical Care Trials Group.
11. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47(9):2756-2764. 10.1128/AAC.47.9.2756-2764.2003, 182644, 12936970.
12. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007, 167(13):1393-1399. 10.1001/archinte.167.13.1393, 17620533.
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG, . Infectious Diseases Society of America; American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72. 10.1086/511159, 17278083, Infectious Diseases Society of America; American Thoracic Society.
14. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128(6):3854-3862. 10.1378/chest.128.6.3854, 16354854.
15. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416. American Thoracic Society; Infectious Diseases Society of America.
16. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35(8):1888-1895. 10.1097/01.CCM.0000275389.31974.22, 17581492.
17. Clinical and Laboratory Standards Institute Performance standards for antimicrobial testing: seventeenth informational supplement. CLSI document M100-S17 2007, Clinical and Laboratory Standards Institute, Wayne, PA, Clinical and Laboratory Standards Institute.
18. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
19. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11(5):550-560. 10.1097/00001648-200009000-00011, 10955408.
20. Suarez D, Haro JM, Novick D, Ochoa S. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J Clin Epidemiol 2008, 61(6):525-530. 10.1016/j.jclinepi.2007.11.007, 18471655.